Identifying Peptide Ligands for CRIP1, a Cancer Biomarker
Author Information
Author(s): Hao Jihua, Serohijos Adrian W. R., Newton Gail, Tassone Gina, Wang Zuncai, Sgroi Dennis C., Dokholyan Nikolay V., Basilion James P.
Primary Institution: Case Western Reserve University
Hypothesis
Can phage display and computational modeling be used to identify high-affinity ligands for CRIP1?
Conclusion
The study successfully redesigned a peptide ligand for CRIP1, improving its binding affinity by approximately 10–28-fold.
Supporting Evidence
- CRIP1 is overexpressed in 90% of invasive and ductal carcinoma in situ breast cancer cases.
- The redesigned peptide A1M showed a significantly improved binding affinity compared to the original peptides.
- Phage display technology was effective in identifying initial peptide ligands for CRIP1.
Takeaway
Researchers found a way to make a tiny piece of protein stick better to a cancer marker, which could help doctors find cancer earlier.
Methodology
The study used phage display technology and computational modeling to identify and redesign peptide ligands for CRIP1.
Limitations
The study did not identify a strong natural binding peptide for CRIP1, suggesting limitations in the phage display library used.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website